

Utah Medicaid Drug Spending (January 2014 - December 2014)

Grouped by Product Description Abbreviation (Includes Drug and Strength)

Rank	Product Form Strength	WAC Cost	Allowed Amount	Claims	Drug Quantity	Days Supply	Unique Recipients
1	SOVALDI TAB 400MG	\$1,000.00	\$5,583,957	206	5,572	5,572	66
2	ABILIFY TAB 5MG	\$25.88	\$5,449,132	6,423	213,238	186,757	1,485
3	LANTUS INJ 100/ML	\$24.85	\$5,297,857	15,324	252,414	408,260	2,698
4	ABILIFY TAB 10MG	\$25.88	\$3,956,699	4,755	154,889	138,253	1,017
5	CYMBALTA CAP 60MG	\$7.27	\$2,979,643	12,881	415,756	381,254	2,617
6	SYNAGIS INJ 100MG/ML	\$2,468.68	\$2,890,140	1,062	1,193	29,993	425
7	HUMALOG INJ 100/ML	\$21.88	\$2,428,944	7,778	135,848	196,117	1,483
8	ABILIFY TAB 15MG	\$25.88	\$2,248,339	3,075	87,879	86,349	569
9	ABILIFY TAB 20MG	\$36.59	\$2,124,069	1,991	58,685	55,768	332
10	VENTOLIN HFA AER	\$2.21	\$1,981,605	44,187	829,246	924,981	20,206
11	FREESTYLE TES LITE	\$1.03	\$1,959,630	12,047	1,367,210	322,886	3,644
12	ABILIFY TAB 2MG	\$25.88	\$1,855,180	2,075	72,617	60,083	548
13	ALDURAZYME INJ 2.9MG/5M	\$161.20	\$1,834,749	102	11,350	1,064	3
14	PULMOZYME SOL 1MG/ML	\$34.44	\$1,829,693	682	54,720	18,830	98
15	KALYDECO TAB 150MG	\$426.72	\$1,688,538	72	4,320	2,160	7
16	NOVOLOG INJ 100/ML	\$20.32	\$1,568,637	4,932	89,705	129,535	991
17	INTUNIV TAB 2MG	\$9.71	\$1,420,943	5,065	159,806	149,036	957
18	CYMBALTA CAP 30MG	\$7.27	\$1,378,991	4,300	193,017	123,738	1,497
19	INVEGA SUST INJ 234/1.5	\$1,251.84	\$1,335,091	724	1,093	18,229	104
20	ADVAIR DISKU AER 250/50	\$6.27	\$1,277,145	4,497	269,843	134,821	1,280
21	SUBOXONE MIS 8-2MG	\$7.04	\$1,258,140	4,099	180,327	94,709	638
22	COPAXONE KIT 20MG/ML	\$185.33	\$1,178,009	233	1,625	6,633	34
23	ABILIFY TAB 30MG	\$36.59	\$1,170,347	1,092	32,596	31,817	203
24	METHYLPHENID TAB 36MG ER	\$6.21	\$1,126,584	6,021	223,441	178,557	1,591
25	OLYSIO CAP 150MG	\$790.00	\$1,121,245	50	1,400	1,400	18
N/A	HARVONI TAB 90-400MG	\$1,125.00	\$1,073,705	35	980	980	20

Notes

1. In cases where there were multiple NDCs for the same drug, form, and strength combination, the WAC is the average WAC.
2. The data includes both fee-for-service and managed care encounter data.
3. Product Form Strength
4. The state entered into an agreement for supplemental rebates for Sovaldi and Harvoni effective 1/1/2015.
5. The state has had to make special funding provisions to cover the cost of these drugs.
6. There is no estimate, currently, of the number of HCV patients in the Medicaid program.